DAE HWA Pharmaceutical Co., Ltd. (KOSDAQ:067080)
15,120
-410 (-2.64%)
At close: Feb 6, 2026
DAE HWA Pharmaceutical Revenue
DAE HWA Pharmaceutical had revenue of 36.73B KRW in the quarter ending September 30, 2025, with 2.57% growth. This brings the company's revenue in the last twelve months to 149.47B, up 1.13% year-over-year. In the year 2024, DAE HWA Pharmaceutical had annual revenue of 149.41B with 5.69% growth.
Revenue (ttm)
149.47B
Revenue Growth
+1.13%
P/S Ratio
1.77
Revenue / Employee
485.28M
Employees
308
Market Cap
264.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 149.41B | 8.05B | 5.69% |
| Dec 31, 2023 | 141.36B | 9.45B | 7.16% |
| Dec 31, 2022 | 131.91B | 14.75B | 12.59% |
| Dec 31, 2021 | 117.16B | 7.81B | 7.15% |
| Dec 31, 2020 | 109.35B | -5.26B | -4.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NOVAREX | 385.76B |
| DongKoo Bio & Pharma | 238.39B |
| Kyung Dong Pharmaceutical | 193.64B |
| GREEN CROSS WellBeing | 151.06B |
| OPTUS Pharmaceutical | 87.58B |
| High Tech Pharm | 75.60B |
| Vivozon Pharmaceutical | 66.40B |
| BL Pharmtech | 6.98B |